{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:29:37Z","timestamp":1786325377647,"version":"build-2736575974"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007680","name":"Naval Medical Research Command","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007680","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Few well-established in vivo animal models reflect the complexity of human malaria infection and immunity, and even fewer have been predictive of the potential of malaria vaccines or prophylactic therapies. Here, we characterized and optimized an\n                      <jats:italic>Aotus nancymaae<\/jats:italic>\n                      non-human primate (NHP) model of\n                      <jats:italic>Plasmodium vivax<\/jats:italic>\n                      (Pv) blood stage infection to enable the testing of novel vaccines and immunoprophylactics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using direct blood stage infection, we selected Vietnam-IV as the most virulent\n                      <jats:italic>P. vivax<\/jats:italic>\n                      strain from seven monkey adapted strains. We next determined the infectious dose with the lowest variability at doses of 0.3 (n\u2009=\u20093), 1.0 (n\u2009=\u20096) and 2.5 (n\u2009=\u20093)\u2009\u00d7\u200910^6 infected red blood cells (iRBC) in spleen-intact\n                      <jats:italic>A. nancymaae<\/jats:italic>\n                      non-human primates (NHPs). In addition, complete blood count (CBC) was measured during blood stage infection. Genomic sequencing was performed for\n                      <jats:italic>P. vivax<\/jats:italic>\n                      Vietnam-IV candidate Duffy Binding Protein-II. Finally, we evaluated the efficacy of a monoclonal antibody (mAb 099100) against DBP-II to protect against blood infection challenge.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>P. vivax<\/jats:italic>\n                      Vietnam-IV monkey adapted strain at dose of 2.5\u2009\u00d7\u200910^6 gave infection kinetics with the lowest coefficient variation (15\u201323%). CBC results at a low (0.3\u2009\u00d7\u200910^6) and high (2.5\u2009\u00d7\u200910^6) dose showed a significant increase in lymphocytes (5.0\u20135.3 to 7.0\u20138.5 10^9\/l) and a decrease of neutrophils (1.9\u20133.0 to 0.6\u20131.2) and platelets (413\u2013458 to 23\u201368 10^9\/l) during acute infection. In a pilot study testing the anti-DBPII mAb 099100, we observed that 1 of 3 monkeys was partially protected against\n                      <jats:italic>P. vivax<\/jats:italic>\n                      as measured by need for treatment intervention (compared with 0 out of 3 monkeys in the control group).\n                      <jats:italic>P. vivax<\/jats:italic>\n                      Vietnam-IV genomic data showed that line was a single clone with a single gene copy of blood stage\n                      <jats:italic>PvDBPII<\/jats:italic>\n                      with single nucleotide polymorphisms outside mAb binding sites.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our study showed a\n                      <jats:italic>P. vivax<\/jats:italic>\n                      blood stage\n                      <jats:italic>A. nancymaae<\/jats:italic>\n                      model with well-characterized clinical, hematological and serological parameters during the course of infection. The challenge appeared stringent and suggests a high titer or high potency of mAb is needed for protection. This model can set the foundation for the evaluation of emerging\n                      <jats:italic>P. vivax<\/jats:italic>\n                      blood stage vaccines, monoclonal antibodies, anti-malarial drugs and prophylactics.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-026-05960-7","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:34:16Z","timestamp":1780500856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of novel Aotus nancymaae non-human primate model for the evaluation of Plasmodium vivax blood stage vaccines and immunoprophylactics"],"prefix":"10.1186","volume":"25","author":[{"given":"Julio A.","family":"Ventocilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Lorena","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredy E.","family":"Villena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cedamanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Buchta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Pannebaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo O.","family":"Valdivia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karli R.","family":"Redinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenore","family":"Carias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berlin","family":"Londono-Renteria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon K.","family":"Wilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"3","key":"5960_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00016-8","volume":"5","author":"P Venkatesan","year":"2024","unstructured":"Venkatesan P. The 2023 WHO world malaria report. Lancet Microbe. 2024;5(3):e214.","journal-title":"Lancet Microbe"},{"issue":"3","key":"5960_CR2","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/cid\/ciz988","volume":"71","author":"L Kai","year":"2020","unstructured":"Kai L, Ying X, Jie LL, Jinhui W, Quan L. Malaria among United Nations peacekeepers in the Democratic Republic of the Congo, South Kivu Area, January 2016-July 2019. Clin Infect Dis. 2020;71(3):698\u2013700.","journal-title":"Clin Infect Dis"},{"issue":"14","key":"5960_CR3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3201\/eid3014.240295","volume":"30","author":"JA Ventocilla","year":"2024","unstructured":"Ventocilla JA, Valdivia HO, Ore M, Santos R, Maguina E, Pannebaker DL, et al. Serosurveillance for Plasmodium falciparum Malaria in Peruvian Army Peacekeeping Personnel, Central African Republic, 2021\u20132022. Emerg Infect Dis. 2024;30(14):80\u20135.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"5960_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4269\/ajtmh.15-0245","volume":"93","author":"DL Saunders","year":"2015","unstructured":"Saunders DL, Garges E, Manning JE, Bennett K, Schaffer S, Kosmowski AJ, et al. Safety, tolerability, and compliance with long-term antimalarial chemoprophylaxis in American soldiers in Afghanistan. Am J Trop Med Hyg. 2015;93(3):584\u201390.","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl 1","key":"5960_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/milmed\/usz304","volume":"185","author":"VE Zottig","year":"2020","unstructured":"Zottig VE, Carr KA, Clarke JG, Shmuklarsky MJ, Kreishman-Deitrick M. Army antimalarial drug development: An advanced development case study for Tafenoquine. Mil Med. 2020;185(Suppl 1):617\u201323.","journal-title":"Mil Med"},{"issue":"8","key":"5960_CR6","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.1016\/S1473-3099(23)00126-3","volume":"23","author":"A Bjorkman","year":"2023","unstructured":"Bjorkman A, Benn CS, Aaby P, Schapira A. RTS,S\/AS01 malaria vaccine-proven safe and effective? Lancet Infect Dis. 2023;23(8):e318\u201322.","journal-title":"Lancet Infect Dis"},{"issue":"10426","key":"5960_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo MS, Dicko A, Tinto H, Ouedraogo JB, Hamaluba M, Olotu A, et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet. 2024;403(10426):533\u201344.","journal-title":"Lancet"},{"issue":"12","key":"5960_CR8","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","volume":"22","author":"MS Datoo","year":"2022","unstructured":"Datoo MS, Natama HM, Some A, Bellamy D, Traore O, Rouamba T, et al. Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial. Lancet Infect Dis. 2022;22(12):1728\u201336.","journal-title":"Lancet Infect Dis"},{"issue":"10287","key":"5960_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","volume":"397","author":"MS Datoo","year":"2021","unstructured":"Datoo MS, Natama MH, Some A, Traore O, Rouamba T, Bellamy D, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. 2021;397(10287):1809\u201318.","journal-title":"Lancet"},{"issue":"6","key":"5960_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1586\/14760584.2016.1141680","volume":"15","author":"K Miura","year":"2016","unstructured":"Miura K. Progress and prospects for blood-stage malaria vaccines. Expert Rev Vaccines. 2016;15(6):765\u201381.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"5960_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41541-020-0196-3","volume":"5","author":"PE Duffy","year":"2020","unstructured":"Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, products. npj Vaccines. 2020;5(1):48.","journal-title":"npj Vaccines"},{"key":"5960_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/biom14010100","author":"E Takashima","year":"2024","unstructured":"Takashima E, Otsuki H, Morita M, Ito D, Nagaoka H, Yuguchi T, et al. The need for novel asexual blood-stage malaria vaccine candidates for Plasmodium falciparum. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/biom14010100.","journal-title":"Biomolecules"},{"key":"5960_CR13","doi-asserted-by":"crossref","unstructured":"Natama HM, Salkeld J, Some A, Soremekun S, Diallo S, Traore O, et al. Safety and efficacy of the blood-stage malaria vaccine RH5.1\/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children. Lancet Infect Dis. 2024.","DOI":"10.1016\/S1473-3099(24)00752-7"},{"issue":"11","key":"5960_CR14","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/infdis\/jiw039","volume":"213","author":"RO Payne","year":"2016","unstructured":"Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, et al. Demonstration of the blood-stage Plasmodium falciparum controlled human malaria infection model to assess efficacy of the P. falciparum apical membrane antigen 1 vaccine, FMP2.1\/AS01. J Infect Dis. 2016;213(11):1743\u201351.","journal-title":"J Infect Dis"},{"issue":"6","key":"5960_CR15","doi-asserted-by":"publisher","first-page":"706","DOI":"10.4161\/hv.19712","volume":"8","author":"CJ Duncan","year":"2012","unstructured":"Duncan CJ, Hill AV, Ellis RD. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother. 2012;8(6):706\u201314.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"5960_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/infdis\/jit156","volume":"208","author":"AD Douglas","year":"2013","unstructured":"Douglas AD, Edwards NJ, Duncan CJ, Thompson FM, Sheehy SH, O\u2019Hara GA, et al. Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection. J Infect Dis. 2013;208(2):340\u20135.","journal-title":"J Infect Dis"},{"issue":"1","key":"5960_CR17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.chom.2014.11.017","volume":"17","author":"AD Douglas","year":"2015","unstructured":"Douglas AD, Baldeviano GC, Lucas CM, Lugo-Roman LA, Crosnier C, Bartholdson SJ, et al. A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe. 2015;17(1):130\u20139.","journal-title":"Cell Host Microbe"},{"key":"5960_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41541-017-0015-7","volume":"2","author":"P Srinivasan","year":"2017","unstructured":"Srinivasan P, Baldeviano GC, Miura K, Diouf A, Ventocilla JA, Leiva KP, et al. A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection. NPJ Vaccines. 2017;2:14.","journal-title":"NPJ Vaccines."},{"issue":"1","key":"5960_CR19","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/s41467-019-09894-4","volume":"10","author":"AD Douglas","year":"2019","unstructured":"Douglas AD, Baldeviano GC, Jin J, Miura K, Diouf A, Zenonos ZA, et al. A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates. Nat Commun. 2019;10(1):1953.","journal-title":"Nat Commun"},{"issue":"10","key":"5960_CR20","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1182\/blood.V99.10.3863","volume":"99","author":"AF Egan","year":"2002","unstructured":"Egan AF, Fabucci ME, Saul A, Kaslow DC, Miller LH. Aotus New World monkeys: model for studying malaria-induced anemia. Blood. 2002;99(10):3863\u20136.","journal-title":"Blood"},{"issue":"4","key":"5960_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4269\/ajtmh.1996.54.380","volume":"54","author":"WE Collins","year":"1996","unstructured":"Collins WE, Galland GG, Sullivan JS, Morris CL, Richardson BB. The Santa Lucia strain of Plasmodium falciparum as a model for vaccine studies. II. Development of Aotus vociferans as a model for testing transmission-blocking vaccines. Am J Trop Med Hyg. 1996;54(4):380\u20135.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"5960_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12936-018-2456-5","volume":"17","author":"M Bermudez","year":"2018","unstructured":"Bermudez M, Moreno-Perez DA, Arevalo-Pinzon G, Curtidor H, Patarroyo MA. Plasmodium vivax in vitro continuous culture: the spoke in the wheel. Malar J. 2018;17(1):301.","journal-title":"Malar J"},{"issue":"7","key":"5960_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004870","volume":"10","author":"K Shaw-Saliba","year":"2016","unstructured":"Shaw-Saliba K, Thomson-Luque R, Obaldia N 3rd, Nunez M, Dutary S, Lim C, et al. Insights into an optimization of Plasmodium vivax Sal-1 in vitro culture: the Aotus primate model. PLoS Negl Trop Dis. 2016;10(7):e0004870.","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"5960_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008864","volume":"17","author":"DN Ndegwa","year":"2021","unstructured":"Ndegwa DN, Kundu P, Hostetler JB, Marin-Menendez A, Sanderson T, Mwikali K, et al. Using Plasmodium knowlesi as a model for screening Plasmodium vivax blood-stage malaria vaccine targets reveals new candidates. PLoS Pathog. 2021;17(7):e1008864.","journal-title":"PLoS Pathog"},{"issue":"9","key":"5960_CR25","doi-asserted-by":"publisher","first-page":"5936","DOI":"10.1128\/IAI.73.9.5936-5944.2005","volume":"73","author":"S Dutta","year":"2005","unstructured":"Dutta S, Kaushal DC, Ware LA, Puri SK, Kaushal NA, Narula A, et al. Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys. Infect Immun. 2005;73(9):5936\u201344.","journal-title":"Infect Immun"},{"issue":"6","key":"5960_CR26","first-page":"429","volume":"44","author":"DC Kaushal","year":"2007","unstructured":"Kaushal DC, Kaushal NA, Narula A, Kumar N, Puri SK, Dutta S, et al. Biochemical and immunological characterization of E coli expressed 42 kDa fragment of Plasmodium vivax and P cynomolgi bastianelli merozoite surface protein-1. Indian J Biochem Biophys. 2007;44(6):429\u201336.","journal-title":"Indian J Biochem Biophys"},{"issue":"1","key":"5960_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1574-695X.2002.tb00600.x","volume":"34","author":"D Bhardwaj","year":"2002","unstructured":"Bhardwaj D, Hora B, Singh N, Puri SK, Lalitha P, Rupa P, et al. Immunogenicity and protective efficacy of three DNA vaccines encoding pre-erythrocytic- and erythrocytic-stage antigens of Plasmodium cynomolgi in rhesus monkeys. FEMS Immunol Med Microbiol. 2002;34(1):33\u201343.","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"8","key":"5960_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101381","volume":"23","author":"C Schafer","year":"2020","unstructured":"Schafer C, Roobsoong W, Kangwanrangsan N, Bardelli M, Rawlinson TA, Dambrauskas N, et al. A Humanized mouse model for Plasmodium vivax to test interventions that block liver stage to blood stage transition and blood stage infection. iScience. 2020;23(8):101381.","journal-title":"iScience."},{"issue":"27\u201330","key":"5960_CR29","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1016\/S0264-410X(03)00455-9","volume":"21","author":"AY Sierra","year":"2003","unstructured":"Sierra AY, Barrero CA, Rodriguez R, Silva Y, Moncada C, Vanegas M, et al. Splenectomised and spleen intact Aotus monkeys\u2019 immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. Vaccine. 2003;21(27\u201330):4133\u201344.","journal-title":"Vaccine"},{"issue":"5 Suppl","key":"5960_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4269\/ajtmh.2005.73.16","volume":"73","author":"A Valderrama-Aguirre","year":"2005","unstructured":"Valderrama-Aguirre A, Quintero G, Gomez A, Castellanos A, Perez Y, Mendez F, et al. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg. 2005;73(5 Suppl):16\u201324.","journal-title":"Am J Trop Med Hyg"},{"issue":"21","key":"5960_CR31","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1016\/j.vaccine.2009.02.083","volume":"27","author":"J Rojas-Caraballo","year":"2009","unstructured":"Rojas-Caraballo J, Mongui A, Giraldo MA, Delgado G, Granados D, Millan-Cortes D, et al. Immunogenicity and protection-inducing ability of recombinant Plasmodium vivax rhoptry-associated protein 2 in Aotus monkeys: a potential vaccine candidate. Vaccine. 2009;27(21):2870\u20136.","journal-title":"Vaccine"},{"issue":"4","key":"5960_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00539-16","volume":"24","author":"N Obaldia 3rd","year":"2017","unstructured":"Obaldia N 3rd, Stockelman MG, Otero W, Cockrill JA, Ganeshan H, Abot EN, et al. A Plasmodium vivax Plasmid DNA- and adenovirus-vectored malaria vaccine encoding blood-stage antigens AMA1 and MSP1(42) in a Prime\/boost heterologous immunization regimen partially protects aotus monkeys against blood-stage challenge. Clin Vaccine Immunol. 2017;24(4):e00539.","journal-title":"Clin Vaccine Immunol"},{"issue":"23","key":"5960_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.152465","volume":"6","author":"AM Minassian","year":"2021","unstructured":"Minassian AM, Themistocleous Y, Silk SE, Barrett JR, Kemp A, Quinkert D, et al. Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly. JCI Insight. 2021;6(23):e152465.","journal-title":"JCI Insight."},{"issue":"704","key":"5960_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf1782","volume":"15","author":"MM Hou","year":"2023","unstructured":"Hou MM, Barrett JR, Themistocleous Y, Rawlinson TA, Diouf A, Martinez FJ, et al. Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection. Sci Transl Med. 2023;15(704):eadf1782.","journal-title":"Sci Transl Med"},{"issue":"2","key":"5960_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4269\/ajtmh.2009.80.228","volume":"80","author":"WE Collins","year":"2009","unstructured":"Collins WE, Sullivan JS, Strobert E, Galland GG, Williams A, Nace D, et al. Studies on the Salvador I strain of Plasmodium vivax in non-human primates and anopheline mosquitoes. Am J Trop Med Hyg. 2009;80(2):228\u201335.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"5960_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1645\/GE-3417RN","volume":"91","author":"WE Collins","year":"2005","unstructured":"Collins WE, Sullivan JS, Galland GG, Williams A, Nace D, Williams T, et al. Observations on the Vietnam Palo Alto strain of Plasmodium vivax in two species of Aotus monkeys. J Parasitol. 2005;91(2):461\u20133.","journal-title":"J Parasitol"},{"issue":"2","key":"5960_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2307\/3279262","volume":"62","author":"WE Collins","year":"1976","unstructured":"Collins WE, Skinner JC, Warren M, Richardson B. Studies on human malaria in Aotus monkey. VII. Comparative infectivity of two strains of Plasmodium vivax to to Anopheles freeborni, A. maculatus, and for strains of A. albimanus. J Parasitol. 1976;62(2):190\u20134.","journal-title":"J Parasitol"},{"issue":"1","key":"5960_CR38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12936-024-04978-z","volume":"23","author":"JA Ventocilla","year":"2024","unstructured":"Ventocilla JA, Tapia LL, Ponce R, Franco A, Leelawong M, Aguiar JC, et al. Evaluation of naturally acquired immune responses against novel pre-erythrocytic Plasmodium vivax proteins in a low endemic malaria population located in the Peruvian Amazon Basin. Malar J. 2024;23(1):163.","journal-title":"Malar J"},{"key":"5960_CR39","doi-asserted-by":"crossref","unstructured":"Cowell AN, Loy DE, Sundararaman SA, Valdivia H, Fisch K, Lescano AG, et al. Selective whole-genome amplification is a robust method that enables scalable whole-genome sequencing of Plasmodium vivax from unprocessed clinical samples. mBio. 2017;8(1).","DOI":"10.1128\/mBio.02257-16"},{"issue":"1","key":"5960_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s44342-024-00012-5","volume":"22","author":"J Makino","year":"2024","unstructured":"Makino J, Ebisuzaki T, Himeno R, Hayashizaki Y. Fast and accurate short-read alignment with hybrid hash-tree data structure. Genomics Inform. 2024;22(1):19.","journal-title":"Genomics Inform"},{"issue":"1","key":"5960_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/cpbi.102","volume":"70","author":"A Prjibelski","year":"2020","unstructured":"Prjibelski A, Antipov D, Meleshko D, Lapidus A, Korobeynikov A. Using SPAdes de novo assembler. Curr Protoc Bioinformatics. 2020;70(1):e102.","journal-title":"Curr Protoc Bioinformatics"},{"issue":"18","key":"5960_CR42","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1093\/bioinformatics\/bty191","volume":"34","author":"H Li","year":"2018","unstructured":"Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018;34(18):3094\u2013100.","journal-title":"Bioinformatics"},{"issue":"1","key":"5960_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13059-019-1829-6","volume":"20","author":"M Alonge","year":"2019","unstructured":"Alonge M, Soyk S, Ramakrishnan S, Wang X, Goodwin S, Sedlazeck FJ, et al. RaGOO: fast and accurate reference-guided scaffolding of draft genomes. Genome Biol. 2019;20(1):224.","journal-title":"Genome Biol"},{"issue":"9","key":"5960_CR44","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.4049\/jimmunol.1801631","volume":"202","author":"LL Carias","year":"2019","unstructured":"Carias LL, Dechavanne S, Nicolete VC, Sreng S, Suon S, Amaratunga C, et al. Identification and characterization of functional human monoclonal antibodies to Plasmodium vivax Duffy-binding protein. J Immunol. 2019;202(9):2648\u201360.","journal-title":"J Immunol"},{"issue":"17","key":"5960_CR45","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1056\/NEJMoa2312775","volume":"390","author":"K Kayentao","year":"2024","unstructured":"Kayentao K, Ongoiba A, Preston AC, Healy SA, Hu Z, Skinner J, et al. Subcutaneous administration of a monoclonal antibody to prevent malaria. N Engl J Med. 2024;390(17):1549\u201359.","journal-title":"N Engl J Med"},{"key":"5960_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12916-015-0324-5","volume":"13","author":"J Hanson","year":"2015","unstructured":"Hanson J, Phu NH, Hasan MU, Charunwatthana P, Plewes K, Maude RJ, et al. The clinical implications of thrombocytopenia in adults with severe falciparum malaria: a retrospective analysis. BMC Med. 2015;13:97.","journal-title":"BMC Med"},{"issue":"4","key":"5960_CR47","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/infdis\/jiu487","volume":"211","author":"DA Lampah","year":"2015","unstructured":"Lampah DA, Yeo TW, Malloy M, Kenangalem E, Douglas NM, Ronaldo D, et al. Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia. J Infect Dis. 2015;211(4):623\u201334.","journal-title":"J Infect Dis"},{"issue":"8","key":"5960_CR48","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1179\/2047773211Y.0000000013","volume":"105","author":"K Saravu","year":"2011","unstructured":"Saravu K, Docherla M, Vasudev A, Shastry BA. Thrombocytopenia in vivax and falciparum malaria: an observational study of 131 patients in Karnataka, India. Ann Trop Med Parasitol. 2011;105(8):593\u20138.","journal-title":"Ann Trop Med Parasitol"},{"issue":"3","key":"5960_CR49","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302524","volume":"7","author":"N Obaldia 3rd","year":"2024","unstructured":"Obaldia N 3rd, Da Silva Filho JL, Nunez M, Glass KA, Oulton T, Achcar F, et al. Sterile protection against P. vivax malaria by repeated blood stage infection in the Aotus monkey model. Life Sci Alliance. 2024;7(3):e202302524.","journal-title":"Life Sci Alliance."},{"key":"5960_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.916702","volume":"12","author":"S Kar","year":"2022","unstructured":"Kar S, Sinha A. Plasmodium vivax duffy binding protein-based vaccine: a distant dream. Front Cell Infect Microbiol. 2022;12:916702.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"5960_CR51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12936-023-04766-1","volume":"22","author":"QD Watson","year":"2023","unstructured":"Watson QD, Carias LL, Malachin A, Redinger KR, Bosch J, Bardelli M, et al. Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein. Malar J. 2023;22(1):369.","journal-title":"Malar J"},{"issue":"7","key":"5960_CR52","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00338-24","volume":"68","author":"N Obaldia 3rd","year":"2024","unstructured":"Obaldia N 3rd. The human malaria-Aotus monkey model: a historical perspective in antimalarial chemotherapy research at the Gorgas Memorial Laboratory-Panama. Antimicrob Agents Chemother. 2024;68(7):e0033824.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5960_CR53","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4269\/ajtmh.2009.80.152","volume":"80","author":"WE Collins","year":"2009","unstructured":"Collins WE, Sullivan JS, Jeffery GM, Williams A, Galland GG, Nace D, et al. The Chesson strain of plasmodium vivax in humans and different species of Aotus monkeys. Am J Trop Med Hyg. 2009;80(1):152\u20139.","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"5960_CR54","doi-asserted-by":"publisher","first-page":"672","DOI":"10.2307\/3285741","volume":"85","author":"JS Sullivan","year":"1999","unstructured":"Sullivan JS, Morris CL, Richardson BB, Galland GG, Jennings VM, Kendall J, et al. Adaptation of the AMRU-1 strain of Plasmodium vivax to Aotus and Saimiri monkeys and to four species of anopheline mosquitoes. J Parasitol. 1999;85(4):672\u20137.","journal-title":"J Parasitol"},{"issue":"4","key":"5960_CR55","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2307\/3281142","volume":"69","author":"WE Collins","year":"1983","unstructured":"Collins WE, Warren M, Skinner JC, Huong AY, Nguyen-Dinh P. Observations on the infectivity of two strains of Plasmodium vivax from Vietnamese refugees to Aotus monkeys and anopheline mosquitoes. J Parasitol. 1983;69(4):689\u201395.","journal-title":"J Parasitol"},{"issue":"3","key":"5960_CR56","doi-asserted-by":"publisher","first-page":"392","DOI":"10.2307\/3282044","volume":"74","author":"WE Collins","year":"1988","unstructured":"Collins WE, Skinner JC, Pappaioanou M, Broderson JR, Ma NS, Filipski V, et al. Infection of Peruvian Aotus nancymai monkeys with different strains of Plasmodium falciparum, P. vivax, and P. malariae. J Parasitol. 1988;74(3):392\u20138.","journal-title":"J Parasitol"},{"issue":"1","key":"5960_CR57","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12936-022-04261-z","volume":"21","author":"S Chakravarty","year":"2022","unstructured":"Chakravarty S, Shears MJ, James ER, Rai U, Kc N, Conteh S, et al. Efficient infection of non-human primates with purified, cryopreserved Plasmodium knowlesi sporozoites. Malar J. 2022;21(1):247.","journal-title":"Malar J"},{"key":"5960_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-14-5","volume":"14","author":"NS Hojo-Souza","year":"2015","unstructured":"Hojo-Souza NS, Pereira DB, Mendes TA, Passos LS, Gazzinelli-Guimaraes AC, Gazzinelli-Guimaraes PH, et al. CD4+ T cells apoptosis in Plasmodium vivax infection is mediated by activation of both intrinsic and extrinsic pathways. Malar J. 2015;14:5.","journal-title":"Malar J"},{"issue":"8","key":"5960_CR59","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/infdis\/jiy296","volume":"218","author":"PAC Costa","year":"2018","unstructured":"Costa PAC, Figueiredo MM, Diniz SQ, Peixoto A, Maloy KJ, Teixeira-Carvalho A, et al. Plasmodium vivax infection impairs regulatory T-Cell suppressive function during acute malaria. J Infect Dis. 2018;218(8):1314\u201323.","journal-title":"J Infect Dis"},{"issue":"1","key":"5960_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-018-0392-9","volume":"7","author":"C Naing","year":"2018","unstructured":"Naing C, Whittaker MA. Severe thrombocytopaenia in patients with vivax malaria compared to falciparum malaria: a systematic review and meta-analysis. Infect Dis Poverty. 2018;7(1):10.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"5960_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2443-x","volume":"17","author":"SS Ourives","year":"2018","unstructured":"Ourives SS, Borges QI, Dos Santos DSA, Melo ECM, de Souza RM, Damazo AS. Analysis of the lymphocyte cell population during malaria caused by Plasmodium vivax and its correlation with parasitaemia and thrombocytopaenia. Malar J. 2018;17(1):303.","journal-title":"Malar J"},{"issue":"2","key":"5960_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012837","volume":"19","author":"Y Nasir","year":"2025","unstructured":"Nasir Y, Molla E, Habtamu G, Sisay S, Ejigu LA, Kassa FA, et al. Spatial distribution of Plasmodium vivax Duffy binding protein copy number variation and Duffy genotype, and their association with parasitemia in Ethiopia. PLoS Negl Trop Dis. 2025;19(2):e0012837.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"5960_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14574-9","volume":"11","author":"J Popovici","year":"2020","unstructured":"Popovici J, Roesch C, Carias LL, Khim N, Kim S, Vantaux A, et al. Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity. Nat Commun. 2020;11(1):953.","journal-title":"Nat Commun"},{"issue":"11","key":"5960_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-019-0587-2","volume":"4","author":"D Urusova","year":"2019","unstructured":"Urusova D, Carias L, Huang Y, Nicolete VC, Popovici J, Roesch C, et al. Author correction: structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP. Nat Microbiol. 2019;4(11):2024.","journal-title":"Nat Microbiol"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05960-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05960-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05960-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:02:38Z","timestamp":1786323758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05960-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5960"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05960-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7660503\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies protocols were reviewed and approved by the U.S. Naval Medical Research Unit SOUTH Institutional Animal Care and Use Committee in compliance with all applicable federal regulations governing the protection of animals and research, NAMRU SOUTH is a center accredited by AAALAC. The experiments reported herein were conducted in compliance with the Animal Welfare Act and in accordance with principles set forth in the \"Guide for the Care and Use of Laboratory Animals,\" Institute of Laboratory Animals Resources, National Research Council, National Academy Press, 2011. These studies were approved via Resoluci\u00f3n Directoral N\u00b0 096\u20132014-SRFOR-DGGSPFFS & N\u00b0 D000218-2020-MINAGRI-SERFOR-DGGSPFFS by the Directorate of Wild Forest and Fauna Management, Peruvian Ministry of Agriculture.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"290"}}